Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBTC Study 23B: Nelfinavir and Rifabutin Interaction in HIV-Related Tuberculosis
NCT00023400Phase 4Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Feb 2000
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of nelfinavir and rifabutin in human immunodeficiency virus infection (HIV) and Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Area Under the Curve and Peak Levels. Started Feb 2000; status: completed.
02
Drugs
nelfinavirrifabutin
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00023400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023400.